Direct Answer
Glaukos is a medical-device and drug-delivery company focused on surgical ophthalmology. Its core business spans minimally invasive glaucoma surgery (MIGS) through the iStent family and sustained drug-delivery implants anchored by iDose TR, a travoprost-eluting device approved by the FDA in 2024. Revenue growth depends on iDose TR commercial execution, surgeon adoption rates and expansion outside the United States.
What Glaukos Does
Glaukos designs, manufactures and sells surgical devices and drug-delivery platforms for ophthalmic conditions, primarily glaucoma and corneal health. The company pioneered the MIGS category with the iStent, a micro-scale trabecular bypass implant placed at the time of cataract surgery to lower intraocular pressure (IOP) without a separate incision or post-operative visit.
The iStent inject W is the current commercial workhorse. iDose TR, launched in the United States in early 2024, is a different product class: a sustained-release implant anchored in the trabecular meshwork that delivers travoprost continuously for approximately 15 months, potentially eliminating daily eye-drop compliance for moderate glaucoma patients.
The corneal health segment, built through the acquisition of Avedro, includes KXL and PHOTREXA for corneal collagen cross-linking (CXL), a procedure that halts keratoconus progression. This segment adds recurring pharmaceutical revenue as each CXL procedure requires a single-use drug kit.
Business Model and Revenue Sources
Glaukos generates revenue from three streams: MIGS devices (iStent inject W and predecessors), sustained drug-delivery implants (iDose TR), and corneal health (KXL systems and PHOTREXA riboflavin kits). The device and pharmaceutical mix creates a degree of consumable revenue: CXL drug kits and iDose TR refill cadence provide predictability beyond pure capital-equipment cycles.
MIGS revenue is largely tied to cataract-surgery volume, because the iStent is almost always implanted simultaneously with phacoemulsification. U.S. cataract volumes are structurally growing as the baby-boomer cohort ages. International markets, particularly Europe and Japan, represent expansion opportunities but face distinct reimbursement timelines.
iDose TR carries a meaningfully higher average selling price than a standalone MIGS stent. The commercial ramp requires educating glaucoma-specialist surgeons on patient selection (moderate glaucoma, poor drop compliance) and procedural technique, which takes time relative to traditional device launches.
Key Metrics to Track
| Metric | Why It Matters |
|---|---|
| iDose TR unit shipments | Primary growth catalyst; commercial ramp pace |
| U.S. MIGS revenue growth | Core business health amid iDose TR transition |
| Corneal health kit revenue | Recurring pharmaceutical mix |
| Gross margin % | iDose TR at premium ASP should expand mix |
| International revenue % | Regulatory and reimbursement progress outside U.S. |
| Operating cash flow | Commercialization spending vs. scale leverage |
Competitive Position
In MIGS, Glaukos competes with Alcon (CyPass was withdrawn, but Alcon remains active in glaucoma with the Hydrus stent acquired through Ivantis in 2022) and New World Medical (Ahmed valve). The iStent family's first-mover advantage, large installed base of trained surgeons and established reimbursement coding give Glaukos strong market position in ab interno trabecular bypass.
iDose TR is, as of mid-2026, the only FDA-approved sustained-release IOP-lowering implant in the trabecular meshwork. This creates a temporary competitive moat while longer-acting formulations or competing platforms work through clinical trials. The moat is durable only as long as iDose TR clinical outcomes justify physician preference over future entrants.
In corneal health, CXL is a niche procedure; KXL faces competition from iLink (Avedro's predecessor product, now embedded in Glaukos) and international systems. The drug-kit model creates barriers because FDA approval ties specific drug formulations to specific device platforms.
Principal Risks
- iDose TR adoption slower than expected: Surgeon training time, patient-selection constraints, and reimbursement coverage gaps could delay the commercial ramp.
- Cataract volume sensitivity: MIGS revenue is tied to cataract-surgery volume, which can soften due to patient deferral, staffing shortages or payer mix shifts.
- Single-market concentration: The majority of revenue is U.S.-derived; international regulatory delays extend the timeline to full global commercialization.
- Pipeline clinical risk: Next-generation sustained-delivery platforms in the pipeline carry typical clinical and regulatory risk.
- Leverage from Avedro acquisition: The balance sheet carries acquisition-related debt; free cash flow must fund both commercialization and debt service.
What to Monitor Each Quarter
- iDose TR shipment volume and management commentary on surgeon adoption trajectory
- U.S. MIGS revenue growth rate versus prior year to gauge whether iDose TR cannibalization or additive revenue is occurring
- Gross margin direction: iDose TR mix benefit should be visible as volumes scale
- Operating expense discipline: commercial build-out vs. earlier-stage spend rates
- International regulatory milestones for iDose TR (CE mark, Japan approval timing)
- Any updates on next-generation iDose platforms or pipeline programs
FAQ
What is the iDose TR and why does it matter for Glaukos investors?
iDose TR is a sustained-release travoprost implant anchored in the trabecular meshwork that delivers IOP-lowering medication continuously for approximately 15 months. It received FDA approval in early 2024 and carries a higher average selling price than the legacy iStent devices. For investors, iDose TR represents the primary near-term revenue growth catalyst and the test of whether Glaukos can expand its revenue opportunity beyond cataract-co-surgery MIGS volume.
How does Glaukos make money from cataract surgery?
Glaukos sells the iStent inject W to ophthalmic surgeons and ambulatory surgery centers. In the United States, the procedure is reimbursed under specific CPT codes when combined with cataract surgery. Because the implant is placed at the time of phacoemulsification, MIGS revenue tracks cataract surgical volume closely. Glaukos does not make money from the cataract surgery itself, only from the stent device and associated implant kit.
What is the corneal health segment?
The corneal health segment, acquired through Avedro, provides KXL light-delivery systems and single-use PHOTREXA riboflavin drug kits for corneal collagen cross-linking (CXL), a procedure that stiffens and stabilizes the cornea to halt keratoconus progression. Each CXL procedure requires the single-use drug kit, creating recurring pharmaceutical revenue. This segment is smaller than MIGS but adds a higher-margin consumable stream.
Who are the main competitors to Glaukos in MIGS?
Alcon, through its 2022 acquisition of Ivantis, markets the Hydrus Microstent, which also targets the Schlemm's canal but via a different mechanism than the iStent. New World Medical offers the Ahmed ClearPath and related filtering devices for more advanced glaucoma. In trabecular bypass, Glaukos holds the dominant market share due to first-mover advantage, surgeon familiarity and reimbursement coding infrastructure built over more than a decade.
Is Glaukos profitable?
As of mid-2026, Glaukos is investing heavily in the iDose TR commercial launch and carries operating losses on a GAAP basis. The company generates positive gross margin and is targeting operating leverage as iDose TR volumes scale and fixed commercial costs are absorbed over a broader revenue base. Investors should track operating cash flow and the trajectory toward operating profitability as the primary financial milestones.
References
- Glaukos Corporation SEC filings (10-K, 10-Q) via SEC EDGAR
- FDA: 510(k) and PMA database for iStent and iDose TR clearances
- American Academy of Ophthalmology guidelines on glaucoma surgical management